NCT01090128View on ClinicalTrials.gov

Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 24, 2017

Study Completion Date

March 24, 2017

Conditions
Stages II-III Breast Cancer
Interventions
DRUG

Nanoparticle Albumin Bound Paclitaxel

IV administered over 30 minutes. 100 mg/m2 on days 1 and 8

DRUG

doxorubicin

50 mg/m2 every 3 weeks

DRUG

cyclophosphamide

500 mg/m2 given every 3 weeks

Trial Locations (1)

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University of Utah

OTHER